Publication

Article

CURE

Spring 2006
Volume5
Issue 1

Taking a Closer Look

Renal cell carcinoma is the most common type of kidney cancer, comprising more than 90 percent of all kidney cancers.

Renal cell carcinoma is the most common type of kidney cancer, comprising more than 90 percent of all kidney cancers. Determining the type of RCC based on genetics and histology helps determine the best treatment and predicts survival. Recent studies involving DNA microarrays show genetic profile expressions can be used to classify renal cell carcinomas more appropriately than histology. The most common subtypes of RCC include the following:

>

Clear-cell RCC is the most common type of RCC, affecting nearly 80 percent of patients. Characterized by clear or pale cells, clear-cell RCC usually occurs in patients age 50 to 70. A mutation in the von Hippel-Lindau gene is responsible for many RCC cases, and is usually the culprit in patients under age 60.

>

Papillary RCC comprises about 10 to 15 percent of all RCC cases and can occur in hereditary or sporadic forms. Sporadic (non-hereditary) papillary RCCs have a five-year survival rate of almost 90 percent. While many papillary tumors carry a good prognosis, a certain subtype characterized by large tumor size, decreased cytokeratin 7, and an increase in an enzyme called topoisomerase II-alpha is particularly aggressive. Often involving both kidneys, papillary RCC sometimes is caused by the loss or excess of specific chromosomes. Papillary RCC occurs more often in African-Americans and is five times more likely to strike men than women.

>

Chromophobe RCC is very rare, occurring in only 5 percent of RCC cases. Tumors are composed of large clear cells. Cases of hereditary chromophobe RCC, called Birt Hogg Dubé syndrome, are caused by a defective gene thought be involved in tumor suppression. This type of RCC often only requires surgery because the cancer rarely metastasizes.

>

Renal oncocytoma is uncommon and rarely deadly. This benign tumor can grow and invade local structures, but does not spread to other parts of the body. Typically treated by surgery, it appears to be caused by the loss of certain chromosomes.

Other types of RCC include collecting duct carcinoma, renal medullary carcinoma, and sarcomatoid RCC, all of which are extremely rare.

Related Videos
CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.
Image of man wearing baseball cap backwards.
Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Image of doctor with brown hair.
Image of man with black hair.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Dr. Catherine Wu is chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston, Massachusetts.
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Related Content